Rhythm Pharmaceuticals Inc Earnings Dividend

Rhythm Pharmaceuticals Inc’s revenue jumped 83.81% since last year same period to $60.11Mn in the Q1 2026. On a quarterly growth basis, Rhythm Pharmaceuticals Inc has generated 4.99% jump in its revenue since last 3-months.

Rhythm Pharmaceuticals Inc’s net profit fell -12.41% since last year same period to $-55.64Mn in the Q1 2026. On a quarterly growth basis, Rhythm Pharmaceuticals Inc has generated -17.12% fall in its net profits since last 3-months.

Rhythm Pharmaceuticals Inc’s net profit margin jumped 38.85% since last year same period to -92.56% in the Q1 2026. On a quarterly growth basis, Rhythm Pharmaceuticals Inc has generated -11.55% fall in its net profit margins since last 3-months.

Rhythm Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.82 - a 0.07% jump from last quarter’s estimates.

Rhythm Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.82.

Rhythm Pharmaceuticals Inc’s earning per share (EPS) fell -2.47% since last year same period to -0.83 in the Q1 2026. This indicates that the Rhythm Pharmaceuticals Inc has generated -2.47% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Rhythm Pharmaceuticals Inc’s return on assets (ROA) stands at -0.3.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Rhythm Pharmaceuticals Inc’s return on equity (ROE) stands at -1.01.